Exicure (XCUR) Stock Price, News & Analysis

Company Overview

Exicure, Inc. was a biotechnology company focused on developing therapeutics based on its spherical nucleic acid (SNA) technology. The company’s platform was designed to deliver nucleic acids into cells and tissues, with the goal of regulating disease-related genes and proteins.

Exicure’s research programs addressed conditions in dermatology, immunology and other therapeutic areas. Its development portfolio included candidates such as AST-005, an SNA-based therapy investigated for psoriasis, along with programs targeting inflammatory and genetic diseases. The company’s work was primarily conducted through research and clinical-development activities rather than commercialized products.

Exicure was headquartered in the Chicago area and had operated as a publicly traded biotechnology company on Nasdaq under the symbol XCUR. Public information about its later operations, current leadership and active development programs is limited, and the company’s status has changed substantially since its earlier clinical-stage period.

Key Stats

• Today's Range: $1.17 to $1.24
• 50-Day Range: $1.15 to $1.93
• 52-Week Range: $1.05 to $9.48
• Volume: 2,571 shs
• Average Volume: 31,306 shs
• Market Capitalization: $7.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Exicure Stock Analysis - MarketRank™

Exicure scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Exicure has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Exicure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Exicure is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exicure is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exicure has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.29% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 1.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently increased by 39.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exicure does not currently pay a dividend.

Dividend Growth

Exicure does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.61

News Sentiment

Exicure has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Exicure this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for XCUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

52.80% of the stock of Exicure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XCUR
• CIK: 1698530
• Web: www.exicuretx.com
• Phone: (847) 673-1707
• Fax: N/A
• Employees: 50
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -237.91%
• Return on Assets: -61.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $500 thousand
• Price / Sales: 15.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 6,550,000
• Free Float: 3,090,000
• Market Cap: $7.89 million
• Optionable: Not Optionable
• Beta: 3.63